Skip to main content
    I

    Inhibrx Biosciences, Inc. (INBX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $77.66
    -5.64 (-6.77%)

    Market Cap: $1.23B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Inhibrx Biosciences, Inc. (INBX) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Inhibrx Biosciences (INBX) to earn -$9.26 per share in the fiscal year ending Dec 31, 2026. Of 4 analysts, 3 rate the stock Buy or Strong Buy, 1 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 0 estimates for the fiscal year ending Dec 31, 2026 were revised up and 1 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 4 ratings average 2.25, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 75% of the ratings.

    RatingAnalystsShare
    Strong Buy00.0%
    Buy375.0%
    Hold125.0%
    Sell00.0%
    Strong Sell00.0%
    Consensus
    Buy
    Total analysts
    4

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus shows a smaller loss.

    Fiscal year ending Dec 31, 2026
    -$9.26
    EPS consensus
    Fiscal year ending Dec 31, 2027
    -$8.76
    EPS consensus, revenue $36.05M
    Next report
    Mar 17, 2027
    Estimated

    EPS range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$9.26-$9.58 to -$8.932N/AN/A3
    Dec 31, 2027-$8.76-$9.05 to -$8.472$36.05M$23.90M to $54.05M3

    Quarterly Estimates

    Quarter endingEPS consensusEPS rangeEPS analysts
    Dec 31, 2026-$2.84-$3.46 to -$2.425

    Estimate Revisions

    Across the 2 periods below, the last 30 days brought 0 upward and 2 downward EPS revisions. Cuts outnumber raises in every period.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202601
    Fiscal year ending Dec 31, 202701

    EPS Trend

    The EPS consensus for the fiscal year ending Dec 31, 2026 has held over the last 90 days.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026-$9.26-$9.26-$9.26-$9.26-$9.26N/A
    Fiscal year ending Dec 31, 2027-$8.76-$8.76-$8.76-$8.76-$6.30N/A

    Frequently Asked Questions About INBX

    What is the INBX stock forecast?

    Consensus analyst estimates put Inhibrx Biosciences's EPS at -$9.26 for the fiscal year ending Dec 31, 2026. The consensus rating from 4 analysts is Buy.

    How do analysts rate INBX stock?

    Of 4 analysts covering Inhibrx Biosciences, 0 rate it Strong Buy, 3 Buy, 1 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from INBX next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$9.26, with estimates from -$9.58 to -$8.93 from 2 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$8.76, with estimates from -$9.05 to -$8.47 from 2 analysts.

    What revenue do analysts expect from Inhibrx Biosciences next year?

    For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $36.05M, with estimates from $23.90M to $54.05M.

    How many analysts cover INBX?

    4 analysts rate Inhibrx Biosciences stock, and 2 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.